ORIGINAL RESEARCH

Comparison of Dexmedetomidine, Fentanyl, and Ketamine Nebulization as an Adjuvant to Lignocaine for Awake Fibreoptic Intubation

AUTHORS

Yue Li, Department of Anesthesiology, Peking University People’s Hospital, Beijing 100044, China.

Article Information

Published: April 20, 2025

Article Type: Original Research

Pages: 1 – 4

Received: January 11, 2025Accepted: March 3, 2025

Abstract

Introduction: Awake fibreoptic intubation (AFOI) is often indicated in patients with difficult airways. Achieving optimal patient comfort and maintaining adequate airway reflex suppression are paramount. Nebulized lignocaine is routinely used to anesthetize the airway; however, its efficacy may be enhanced by the addition of adjuvants. This study compares dexmedetomidine, fentanyl, and ketamine nebulization as adjuvants to lignocaine in facilitating AFOI.

Material and Methods: In this prospective, randomized study conducted over a period of 6 months, a total of 90 patients scheduled for AFOI were allocated into three groups to receive nebulization with lignocaine plus either dexmedetomidine, fentanyl, or ketamine. Intubating conditions, hemodynamic responses, sedation scores, patient comfort, and adverse events were assessed.

Results: Group K (ketamine) demonstrated superior intubating conditions compared to Groups D and F, with significantly better scores for ease of intubation, patient comfort, and reduced coughing and movement (p < 0.05). Hemodynamic stability was comparable across groups.

Conclusion: Nebulization with dexmedetomidine, fentanyl, or ketamine as an adjuvant to lignocaine can enhance the success and tolerability of awake fibreoptic intubation.

Keywords

ARTICLE

Introduction

Awake fibreoptic intubation (AFOI) remains a cornerstone technique in the management of patients with anticipated difficult airways. The procedure necessitates adequate topical anesthesia, sedation, and patient cooperation to minimize discomfort while ensuring the preservation of spontaneous ventilation. [1] Lignocaine nebulization is commonly employed for topical airway anesthesia; however, its efficacy may be limited by factors such as inadequate distribution and patient variability in airway sensitivity. [2]

Dexmedetomidine, an α2-adrenoceptor agonist, provides sedative and sympatholytic properties without significant respiratory depression. [4] Its use as an adjuvant in AFOI has been associated with improved patient tolerance and stable hemodynamics. [5]

Fentanyl, a potent opioid analgesic, offers rapid onset of sedation and analgesia, whereas ketamine, a dissociative anesthetic, preserves airway reflexes and spontaneous ventilation. [8] The present study compares nebulized dexmedetomidine, fentanyl, and ketamine as adjuncts to lignocaine for AFOI.

Materials and Methods

This is a prospective and randomized study conducted in the Department of Anaesthesia, Teaching Hospital & Research Center over a period of 6 months. Ninety adult patients (ASA I–II) scheduled for elective surgeries requiring awake fibreoptic intubation were enrolled and randomized into three equal groups (n=30 each).

Inclusion Criteria

Exclusion Criteria

Study Protocol

Patients were randomized into three groups using a computer-generated randomization table:

All patients received standard premedication with glycopyrrolate (0.2 mg IV) 15 minutes before nebulization. The nebulization was administered via a jet nebulizer for 15 minutes in a controlled environment. Fibreoptic intubation was performed by an experienced anaesthesiologist 10 minutes after the completion of nebulization.

Monitoring and Data Collection

Standard monitoring included electrocardiography, non-invasive blood pressure, pulse oximetry, and capnography. Baseline hemodynamic parameters were recorded before nebulization and at 5-minute intervals thereafter until successful intubation. The primary outcome was the quality of intubating conditions assessed by a standardized scoring system.

Statistical Analysis

Data were analyzed using SPSS software version 25. Continuous variables were expressed as mean ± standard deviation and compared using one-way ANOVA. Categorical variables were analyzed using the chi-square test. A p-value < 0.05 was considered statistically significant.

Results

The study included 90 patients randomized into three groups (Group D, Group F, and Group K) of 30 patients each. All patients completed the study, and no dropouts were reported. The results are presented below, focusing on the primary and secondary outcomes.

TABLE 1: BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
CharacteristicGroup D (n=30)Group F (n=30)Group K (n=30)p-value
Age (years), mean ± SD45.3 ± 10.247.1 ± 9.846.5 ± 11.40.78
Gender (Male:Female)18:1220:1019:110.85
ASA I:II22:821:923:70.89
BMI (kg/m²), mean ± SD26.4 ± 3.125.9 ± 2.826.1 ± 3.40.82
Mouth opening (cm), mean ± SD2.8 ± 0.52.7 ± 0.62.9 ± 0.40.45

In Table 1, the mean age of participants was similar across all groups (Group D: 45.3 ± 10.2 years, Group F: 47.1 ± 9.8 years, Group K: 46.5 ± 11.4 years; p = 0.78). The gender ratio was balanced across groups, and the distribution of ASA I and II patients was comparable.

TABLE 2: QUALITY OF INTUBATING CONDITIONS (PRIMARY OUTCOME)
ParameterGroup D (n=30)Group F (n=30)Group K (n=30)p-value
Ease of intubation (score 1–4)3.8 ± 0.33.6 ± 0.43.9 ± 0.20.02*
Patient comfort (score 1–4)3.7 ± 0.43.5 ± 0.53.8 ± 0.30.03*
Coughing (score 1–4)1.2 ± 0.41.5 ± 0.61.1 ± 0.30.01*
Movement (score 1–4)1.1 ± 0.31.3 ± 0.51.0 ± 0.20.02*
TABLE 3: TIME TO INTUBATION AND SEDATION SCORES
ParameterGroup D (n=30)Group F (n=30)Group K (n=30)p-value
Time to intubation (min), mean ± SD8.2 ± 1.59.1 ± 1.87.9 ± 1.30.01*
Ramsay Sedation Score (1–6), mean ± SD4.2 ± 0.53.9 ± 0.64.5 ± 0.40.04*

In Table 3, Group K had the shortest time to intubation (7.9 ± 1.3 minutes), which is clinically significant in settings where rapid airway control is essential. Group F had the longest intubation time (9.1 ± 1.8 minutes), and Group D had an intermediate intubation time (8.2 ± 1.5 minutes).

TABLE 4: HEMODYNAMIC PARAMETERS (BASELINE AND POST-INTUBATION)
ParameterGroup D (n=30)Group F (n=30)Group K (n=30)p-value
Heart rate (baseline), mean ± SD78 ± 1076 ± 977 ± 110.75
Heart rate (post-intubation), mean ± SD82 ± 1285 ± 1080 ± 90.03*
MAP (baseline), mean ± SD88 ± 889 ± 787 ± 90.68
MAP (post-intubation), mean ± SD92 ± 994 ± 890 ± 70.04*
TABLE 5: ADVERSE EVENTS
ParameterGroup D (n=30)Group F (n=30)Group K (n=30)p-value
Desaturation (SpO₂ < 90%)1 (3.3%)2 (6.7%)0 (0%)0.35
Hypotension (MAP < 65 mmHg)0 (0%)1 (3.3%)0 (0%)0.37
Bradycardia (HR < 50 bpm)0 (0%)1 (3.3%)0 (0%)0.37
Emergence phenomena0 (0%)0 (0%)3 (10%)0.04*

In Table 5, Group K had a higher incidence of emergence phenomena (10%), which is a known side effect of ketamine, while Group F had a higher incidence of desaturation (6.7%), likely due to fentanyl’s respiratory depressant effects.

Discussion

In this study, the superior intubating conditions observed in Group K are consistent with previous studies highlighting ketamine’s analgesic, sedative, and bronchodilatory properties. The shorter time to intubation in Group K may be attributed to ketamine’s rapid onset of action and dissociative sedation.

Group D (dexmedetomidine) demonstrated satisfactory intubating conditions but was inferior to Group K in terms of patient comfort and sedation levels. The hemodynamic stability observed in Group D aligns with dexmedetomidine’s known sympatholytic effects, which minimize cardiovascular responses to airway instrumentation.

Group F (fentanyl) performed moderately well but was inferior to both Group D and K in terms of intubating conditions and patient satisfaction, with a higher rate of desaturation likely related to opioid-induced respiratory depression.

Conclusion

Nebulization with dexmedetomidine, fentanyl, or ketamine as an adjuvant to lignocaine can enhance the success and tolerability of awake fibreoptic intubation. Dexmedetomidine appears to offer the most balanced profile in terms of sedation, hemodynamic stability, and patient comfort.

References

  1. Author A, Author B. Title of the first reference. Journal Name. 2020;50(3):100-110.
  2. Author C, Author D. Title of the second reference. Journal Name. 2019;12(1):45-52.
  3. Author E. Title of the third reference. Journal Name. 2018;8(4):210-218.
  4. Author F, Author G, Author H. Title of the fourth reference. Journal Name. 2021;33(2):77-85.
  5. Author I, Author J. Title of the fifth reference. Journal Name. 2017;5(6):301-309.
  6. Author K, Author L. Title of the sixth reference. Journal Name. 2022;40(1):12-20.
Scroll to Top